Linker-Payload Risk Is Where The Bar Is Rising

This segment of the Outsourced Pharma Live event, “ADC Outsourcing: Plan Smart Now Or Suffer Later,” focuses on where the highest technical and regulatory risks sit in ADC manufacturing, especially when programs involve novel linker-payload chemistry, new mechanisms, or emerging drug-antibody conjugate approaches. Ben and Reza explain why sponsors need to understand the innovation point in their molecule, how impurities or instability can undermine the program, and why linker-payload and bioconjugation risk are often underestimated. Featuring Benjamin Hutchins, Ph.D., Founder & Principal Consultant, First Principles CMC, and Reza Oliyai, Ph.D., President and CEO, Oliyai Consulting Corporation.